ReviewJournal of biomedicine & biotechnology2010
IL-10 and TNFalpha genotypes in SLE.
Review in Journal of biomedicine & biotechnology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Meta-analysis of associations between interleukin-10 polymorphisms and susceptibility to Behcet's disease.Immunologic research · 2019Pooled it
- Lack of association between the haplotype GCC/ATA polymorphism in the IL-10 promoter and SLE risk: evidence from a meta-analysis.Zeitschrift fur Rheumatologie · 2013Pooled it
- Association of tumor necrosis factor α (rs1800629) and interleukin-10 (rs1800896) gene polymorphisms with systemic lupus erythematosus: a meta-analysis.Reumatologia · 2025Review
- Melatonin, an Antitumor Necrosis Factor Therapy.Journal of pineal research · 2025Review
- New immunological aspects of peri-implantitis.Einstein (Sao Paulo, Brazil) · 2024Article
- The circRNA-miRNA-mRNA regulatory network in plasma and peripheral blood mononuclear cells and the potential associations with the pathogenesis of systemic lupus erythematosus.Clinical rheumatology · 2023Review
- Dual Role of Interleukin-10 in Murine NZB/W F1 Lupus.International journal of molecular sciences · 2021Article
- Correlations of Expression Levels of a Panel of Genes (BioMed research international · 2019Article
- Protective role of adenovirus vector-mediated interleukin-10 gene therapy on endogenous islet β-cells in recent-onset type 1 diabetes in NOD mice.Experimental and therapeutic medicine · 2016Article
- Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation.Mediators of inflammation · 2015Review
- Significant roles played by IL-10 in Chlamydia infections.Inflammation · 2014Review
- Is the IL-10 -819 polymorphism associated with visceral leishmaniasis?Inflammation · 2013Article
- The applied basic research of systemic lupus erythematosus based on the biological omics.Genes and immunity · 2013Review
- Is the IL-10 promoter polymorphism at position -592 associated with immune system-related diseases?Inflammation · 2013Review
- Article
- Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus.Molecular biology reports · 2013Article
- Interleukin (IL)-10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: a study of patients from the southeast region of Iran.Inflammation · 2012Article
- A whole genome methylation analysis of systemic lupus erythematosus: hypomethylation of the IL10 and IL1R2 promoters is associated with disease activity.Genes and immunity · 2012Article
- Dextran sodium sulphate colitis mouse model: traps and tricks.Journal of biomedicine & biotechnology · 2012Review
- Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease.Critical reviews in immunology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The production of two regulators of the inflammatory response, interleukin 10 (IL-10) and tumor necrosis factor alpha (TNFalpha), has been found to be deeply deregulated in SLE patients, suggesting that these cytokines may be involved in the pathogenesis of the disease. Genetic polymorphisms at the promoter regions of IL-10 and TNFalpha genes have been associated with different constitutive and induced cytokine production. Given that individual steady-state levels of these molecules may deviate an initial immune response towards different forms of lymphocyte activation, functional genetic variants in their promoters could influence the development of SLE. The present review summarizes the information previously reported about the involvement of IL-10 and TNFalpha genetic variants on SLE appearance, clinical phenotype, and outcome. We show that, in spite of the heterogeneity of the populations studied, the existing knowledge points towards a relevant role of IL-10 and TNFalpha genotypes in SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.